-
Pretty in pink: Dallas World Cup venue chasing perfect pitch
-
Wordle heads to primetime as media seek puzzle reinvention
-
Eurovision: the grand final running order
-
McIlroy, back in PGA hunt, blames bad setup for lead logjam
-
Kubo vows to lead Japan at World Cup with Mitoma out
-
McNealy and Smalley share PGA lead at difficult Aronimink
-
Drake drops three albums at once
-
Boeing confirms China commitment to buy 200 aircraft
-
Knicks forward Anunoby trains as NBA Eastern Conference finals loom
-
American McNealy grabs PGA lead at difficult Aronimink
-
Substitute 'keeper sends Saint-Etienne into promotion play-off
-
Sinner's bid to reach Italian Open final held up by Roman rain
-
Aston Villa humble Liverpool to secure Champions League qualification
-
US says Iran-backed militia commander planned Jewish site attacks
-
Bolivia unrest continues despite government deal with miners
-
Scheffler slams 'absurd' PGA pin locations
-
New deadly Ebola outbreak hits DR Congo, 1 dead in Uganda
-
Democrats accuse Trump of stock trade corruption
-
'Beyond the Oscar': Travolta gets surprise Cannes prize
-
Israel, Lebanon say extending ceasefire despite new strikes
-
Potgieter grabs early PGA lead at difficult Aronimink
-
Prosecutors seek death penalty for US man charged with killing Israeli embassy staffers
-
Judge declares mistrial in Weinstein sex assault case
-
Canada takes key step towards new oil pipeline
-
Iranian filmmaker Farhadi condemns Middle East war, protest massacres
-
'Better than the Oscar': John Travolta gets surprise Cannes prize
-
Marsh muscle motors Lucknow to victory over Chennai
-
Judge declares mistrial in Weinstein case as jury fails to reach verdict
-
Eurovision finalists tune up as boycotting Spain digs in
-
Indonesia's first giant panda is set to charm the public
-
Cheer and tears as African refugee rap film 'Congo Boy' charms Cannes
-
Norwegian Ruud rolls into Italian Open final, Sinner set for Medvedev clash
-
Bolivia government says deal reached with protesting miners
-
Showdowns and spycraft on Trump-Xi summit sidelines
-
Smalley seizes PGA lead with Matsuyama making a charge
-
Acosta quickest in practice for Catalan MotoGP
-
Nuno wants VAR 'consistency' as West Ham fight to avoid relegation
-
Vingegaard powers to maiden Giro stage victory
-
Iran to hold pre-World Cup training camp in Turkey: media
-
US scraps deployment of 4,000 troops to Poland
-
Ukraine vows more strikes on Russia after attack on Kyiv kills 24
-
Bayern veteran Neuer signs one-year contract extension
-
Ukraine can down Russian drones en masse. But missiles are a problem
-
Israeli strikes wound dozens in Lebanon as talks in US enter second day
-
'Everybody wants Hearts to win', says Celtic's O'Neill ahead of title decider
-
Scheffler stumbles from share of lead at windy PGA
-
New deadly Ebola outbreak hits DR Congo
-
Farke calls for Leeds owners to match his ambition
-
Zverev pulls out of home event in Hamburg with back injury
-
Xi, Trump eke small wins from talks but no major deals: analysts
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.Thomson--BTB